Skip to main content
. Author manuscript; available in PMC: 2020 Dec 15.
Published in final edited form as: J Immunol. 2019 Nov 6;203(12):3407–3415. doi: 10.4049/jimmunol.1900364

Figure 4.

Figure 4.

Efficacy of NX-13 in CD45RBhi adoptive transfer. Rag2−/− were adoptively transferred 4×105 naïve CD4+ T cells and treated daily with oral NX-13 (10 mg/kg). Mice were scored twice weekly for disease activity until eight weeks post-transfer (A). Colon histology was scored at 8 weeks post-transfer for leukocytic infiltration (B), mucosal thickening (C), and epithelial erosion (D). Representative photomicrographs of H&E stained colon from vehicle (E) and 10 mg/kg NX-13 (L) groups; asterisks mark leukocytic infiltration, bars mark mucosal thickening (scale bar, 100 μm). Th1 (G, CD4+ CD8- Tbet+ IFNγ+), Th17 (H, CD4+ CD8- RORγT+ IL17+), Treg (I, CD4+ CD25+ FOXP3+ IL10+), and neutrophils (J, Gr1hi CD11b+) were quantified by flow cytometry in colon at eight weeks post-transfer. Data presented as mean ± SEM (n = 10). Asterisks mark significance (p ≤ 0.05).